CAJ | 학술논문

前列腺癌是老年男性常见的恶性肿瘤，内分泌治疗虽可使大多数患者的病情得到控制和改善，但在经过一段时间的缓解后，绝大多数患者会发展为预后极差的去势难治性前列腺癌（CRPC）。对CRPC患者如何实施个体化治疗，以最小的不良反应和最大的获益来延长生存已成为临床工作者亟待解决的难题。目前临床上采用的分级分期方法很难准确预测具有复杂生物学行为的CRPC患者的预后。近年许多肿瘤标志物相继被发现并用于CRPC患者的预后判断，本文对影响CRPC预后的分子标志物做一综述。
전렬선암시노년남성상견적악성종류，내분비치료수가사대다수환자적병정득도공제화개선，단재경과일단시간적완해후，절대다수환자회발전위예후겁차적거세난치성전렬선암（CRPC）。대CRPC환자여하실시개체화치료，이최소적불량반응화최대적획익래연장생존이성위림상공작자극대해결적난제。목전림상상채용적분급분기방법흔난준학예측구유복잡생물학행위적CRPC환자적예후。근년허다종류표지물상계피발현병용우CRPC환자적예후판단，본문대영향CRPC예후적분자표지물주일종술。
Prostate cancer is one of the most common malignant tumors among males, and nearly all patients will inevitably de-velop castration-resistant prostate cancer (CRPC). The prognosis of CRPC patients is very poor. How to implement the individualized treatment plan with minimal side effects and optimum benefit as well as how to prolong the patients' lives have recently become impor-tant issues. Current staging and grading systems fail to provide accurate prognoses of most CRPC, which have complicated biological behaviors. Over the past few years, a host of tumor molecular markers have been discovered and can provide prognostic information for CRPC. This review summarizes the molecular prognostic biomarkers that affect the prognosis of CRPC.